Skip to content
Menu

Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.

Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.

Read at benzinga.com

← All stock news